Regeneron Announces VEGF Trap Clinical Update.TARRYTOWN, N.Y. -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and sanofi-aventis are collaborating on the development of Regeneron's Vascular Endothelial Growth Factor Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). (VEGF VEGF vascular endothelial growth factor. ) Trap in oncology. On February 13, 2007, sanofi-aventis will report its 2006 annual results and review its development pipeline. As part of this review, sanofi-aventis will provide an update of the VEGF Trap clinical program. The presentation is scheduled to be webcast live beginning at 8:30 a.m. Paris Time (2:30 a.m. Eastern Time) and can be accessed through the sanofi-aventis website (www.sanofi-aventis.com) at the time of the presentation. An archived version of the presentation will be available after the live webcast on the sanofi-aventis website. Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions See carpal tunnel syndrome, computer vision syndrome, dry eyes and deep vein thrombosis. . Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases Noun 1. inflammatory disease - a disease characterized by inflammation disease - an impairment of health or a condition of abnormal functioning NEC, necrotizing enterocolitis - an acute inflammatory disease occurring in the intestines of premature infants; and has preclinical programs in other diseases and disorders. During this webcast, sanofi-aventis will discuss historical information and include forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. about Regeneron and the VEGF Trap oncology program, which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of our product candidates, determinations by regulatory and administrative governmental authorities which delay or restrict our ability to continue to develop or commercialize our product candidates, competing drugs that are superior to our product candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement, including our agreement with sanofi-aventis, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Securities and Exchange Commission (SEC), including its Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2005 and its Form 10-Q Form 10-Q See 10-Q. for the quarter ended September 30, 2006. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law. Additional information about Regeneron and recent news releases are available on Regeneron's worldwide web site at www.regeneron.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion